Recent Agents Targeting HIF-1α for Cancer Therapy

被引:164
作者
Hu, Yaozhong [1 ,2 ]
Liu, Jing [1 ,2 ]
Huang, He [1 ,2 ]
机构
[1] Tianjin Univ, Sch Chem Engn & Technol, Dept Biochem Engn, Tianjin 300072, Peoples R China
[2] Tianjin Univ, Minist Educ, Key Lab Syst Bioengn, Tianjin 300072, Peoples R China
关键词
HIF-1; alpha; CHEMICAL INHIBITORS; PROTEIN AND NUCLEIC ACID INHIBITORS; VHH; CANCER; TARGETED THERAPY; HYPOXIA-INDUCIBLE-FACTOR; ENDOTHELIAL-GROWTH-FACTOR; FIH-MEDIATED REPRESSION; INHIBITS TUMOR-GROWTH; FACTOR-I; DNA-BINDING; VEGF EXPRESSION; TRANSCRIPTIONAL ACTIVITY; FACTOR-1-ALPHA PROTEIN; INDUCED ANGIOGENESIS;
D O I
10.1002/jcb.24390
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The discovery of hypoxia-inducible factor-1 (HIF-1) has led to an increasing understanding of the mechanism of tumor hypoxia in the past two decades. As a key transcriptional regulator, HIF-1 plays a central role in the adaptation of tumor cells to hypoxia by activating the transcription of targeting genes, which regulate several biological processes including angiogenesis, cell proliferation, survival, glucose metabolism and migration. The inhibitors of HIF-1 in cancer have provided us a new clue for the targeting cancer therapy. This review will introduce the general knowledge of the biology characteristic of HIF-1 and mechanism of O2-dependent regulation. Moreover, a number of chemical inhibitors plus protein and nucleic acid inhibitors are included and classified mainly based on their different mechanism of inhibiting action. We also prefer to discuss the advantages of protein and nucleic acid inhibitors compared with chemical inhibitors. J. Cell. Biochem. 114: 498509, 2013. (C) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:498 / 509
页数:12
相关论文
共 89 条
[1]
Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells -: Protective role in apoptosis [J].
Alvarez-Tejado, M ;
Naranjo-Suárez, S ;
Jiménez, C ;
Carrera, AC ;
Landázuri, MO ;
del Peso, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) :22368-22374
[2]
Resveratrol: A review of preclinical studies for human cancer prevention [J].
Athar, Mohammad ;
Back, Jung Ho ;
Tang, Xmwel ;
Kim, Kwang Ho ;
Kopelovich, Levy ;
Bickers, David R. ;
Kim, Arianna L. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 224 (03) :274-283
[3]
Phage display technology: clinical applications and recent innovations [J].
Azzazy, HME ;
Highsmith, WE .
CLINICAL BIOCHEMISTRY, 2002, 35 (06) :425-445
[4]
Hypoxia inducible factor-1: a novel target for cancer therapy [J].
Belozerov, VE ;
Van Meir, EG .
ANTI-CANCER DRUGS, 2005, 16 (09) :901-909
[5]
A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261 [J].
Bible, Keith C. ;
Peethambaram, Prema P. ;
Oberg, Ann L. ;
Maples, William ;
Groteluschen, David L. ;
Boente, Matthew ;
Burton, Jill K. ;
Dahl, Leigh C. Gomez ;
Tibodeau, Jennifer D. ;
Isham, Crescent R. ;
Maguire, Jacie L. ;
Shridhar, Viji ;
Kukla, Andrea K. ;
Voll, Kalli J. ;
Mauer, Mathew J. ;
Colevas, Alexander D. ;
Wright, John ;
Doyle, L. Austin ;
Erlichman, Charles .
GYNECOLOGIC ONCOLOGY, 2012, 127 (01) :55-62
[6]
Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma [J].
Bishayee, Anupam ;
Politis, Themos ;
Darvesh, Altaf S. .
CANCER TREATMENT REVIEWS, 2010, 36 (01) :43-53
[7]
Flavopiridol, an inhibitor of transcription - Implications, problems and solutions [J].
Blagosklonny, MV .
CELL CYCLE, 2004, 3 (12) :1537-1542
[8]
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies [J].
Bose, Prithviraj ;
Perkins, Edward B. ;
Honeycut, Connie ;
Wellons, Martha D. ;
Stefan, Tammy ;
Jacobberger, James W. ;
Kontopodis, Emmanouil ;
Beumer, Jan H. ;
Egorin, Merrill J. ;
Imamura, Chiyo K. ;
Figg, W. Douglas, Sr. ;
Karp, Judith E. ;
Koc, Omer N. ;
Cooper, Brenda W. ;
Luger, Selina M. ;
Colevas, A. Dimitrios ;
Roberts, John D. ;
Grant, Steven .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) :1657-1667
[9]
New phosphatidylinositol 3-kinase inhibitors for cancer [J].
Bowles, Daniel W. ;
Jimeno, Antonio .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (04) :507-518
[10]
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo [J].
Cejka, Daniel ;
Preusser, Matthias ;
Woehrer, Adelheid ;
Sieghart, Wolfgang ;
Strommer, Sabine ;
Werzowa, Johannes ;
Fuereder, Thorsten ;
Wacheck, Volker .
CANCER BIOLOGY & THERAPY, 2008, 7 (09) :1379-1387